OXFORD, England, December 9 /PRNewswire/ --
- Appointment Follows Recent Recruitment of Senior Antibody Industry Leaders and Highlights OBT's Growth Into a Leading Oncology-Focused Therapeutic Antibody Company
Oxford BioTherapeutics (OBT) has today announced the appointment of Dr Michael Moore as non-executive Chairman. Dr Moore brings considerable expertise and experience to OBT at an exciting phase in the Company's development, as it capitalises on partnerships with GSK, Amgen, Medarex and Biosite to build a broad pipeline of therapeutic antibodies in oncology.
Dr Moore has several decades of senior management experience in the biotechnology sector and joins the Board of OBT following five years at UK biotechnology company, Piramed Limited, where he was CEO until its acquisition by Roche in 2008. Prior to joining Piramed, Dr Moore was CSO and Research Director of Xenova Group plc. During a distinguished career he has also held senior academic positions at the Paterson Institute for Cancer Research, Christie Hospital, Manchester, UK and the Brunel Institute of Cancer Genetics and Pharmacogenomics where he is still Professor Associate.
Today's announcement follows OBT's recent recruitment of a number of other senior industry leaders in the biologics field and heralds another important milestone for the Company, as it matures into a global leader in the rapidly developing oncology therapeutic antibody sector. The company recently announced the appointment of Jim Cornett, Chief Operating Officer, Mike Gresser, Chief Scientific Officer, and Jon Terrett, VP Oncology, to lead its US R&D operations.
Dr Moore commented, "I am delighted to join Oxford BioTherapeutics at
this exciting time in the Company's development. I have been highly impressed
by OBT's scientific and commercial approach and am very pleased to join the
other distinguished members of the OBT Board and
|SOURCE Oxford BioTherapeutics (OBT)|
Copyright©2009 PR Newswire.
All rights reserved